Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $26.67

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) have been given a consensus recommendation of "Buy" by the nine analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $26.67.

A number of brokerages have recently weighed in on LQDA. Needham & Company LLC restated a "buy" rating on shares of Liquidia in a research report on Monday, June 2nd. Scotiabank increased their price target on Liquidia from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. HC Wainwright lifted their price objective on Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, May 28th. Raymond James upped their price objective on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Finally, Wells Fargo & Company increased their target price on Liquidia from $20.00 to $23.00 and gave the company an "overweight" rating in a research report on Wednesday, May 28th.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the transaction, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares in the company, valued at approximately $13,657,119.40. This represents a 1.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock valued at $450,233 in the last ninety days. Insiders own 26.50% of the company's stock.

Hedge Funds Weigh In On Liquidia

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Liquidia by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock worth $41,834,000 after purchasing an additional 115,367 shares during the period. LM Advisors LLC bought a new position in shares of Liquidia during the fourth quarter valued at approximately $25,948,000. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 16.8% in the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock worth $23,370,000 after buying an additional 285,220 shares during the period. Vestal Point Capital LP raised its holdings in shares of Liquidia by 17.3% in the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock worth $20,698,000 after buying an additional 260,000 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Liquidia by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after acquiring an additional 101,597 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Stock Down 16.9%

LQDA stock traded down $3.04 during midday trading on Tuesday, hitting $14.98. The company's stock had a trading volume of 11,658,140 shares, compared to its average volume of 1,169,973. Liquidia has a 12 month low of $8.26 and a 12 month high of $19.41. The company has a 50 day moving average of $15.04 and a two-hundred day moving average of $14.08. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.19 and a beta of 0.04.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).